MONROVIA, CA, January 24, 2009
/24-7PressRelease/ -- Sue Richards, Ph.D., Group Vice President of Clinical Laboratory Sciences at Genzyme Corporation in Framingham, MA will give the keynote address entitled "Immunogenicity of Protein Therapeutics: Strategies and Implications." at GTCbio's 3rd annual Immunodiagnostics & Immunomonitoring Conference on April 23-24, 2009 in Chicago, IL.
Dr. Richards will provide the attendees with an overview of immunogenicity of recombinant human therapeutic proteins. She will explain risk-based assessment and provide a strategy for immunomonitoring. She will also provide analytical approaches to assess immunogenicity and clinical consequences of anti-drug antibodies.
Dr. Richards has been at Genzyme for twenty years and is responsible for directing and supervising the Immunology and Clinical Laboratory Science Departments. Dr. Richards worked for E.I. Dupont de Nemours & Co. for five years in the Medical Products Division prior to joining Genzyme. Dr. Richards received her Ph.D. in Microbiology from SUNY at Buffalo, and completed a postdoctoral fellowship at the Wadsworth Center for Laboratories and Research in Albany, NY in the Vaccinia Virus Vaccine Program.
Dr. Richards' presentation, along with over 25 other distinguished speakers, can be heard by attending the 3rd Annual Immunodiagnostics & Immunomonitoring Conference on April 23-24, 2009 in Chicago, IL. The conference will cover novel approaches & methods for immunodiagnostics, evaluation of innovative immunodiagnostic techniques, immunomonitoring of clinical trials, innovative techniques for future clinical use, and biomarkers in immunodiagnostics & immunomonitoring. For more information visit http://gtcbio.com/conferenceDetails.aspx?id=147
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Joost Oppenheim, M.D., Laboratory Chief - NCI, to give Keynote Presentation at GTCbio's 8th Cytokines & Inflammation Conference on January 28-29, 2010 in San Diego, CA
- Vaccines: All Things Considered Conference to be held by GTCbio on November 9-10, 2009 in Washington, DC
- Translational Medicine Track of the GTCbio 5th Annual Modern Drug Discovery & Development Conference to be held on October 14-16, 2009 in San Diego, CA
- Amy Scott-Billman, VP at GlaxoSmithKline to do Keynote at Modern Drug Discovery & Development Summit
- Biological Therapeutics to be an Important Focus at the 5th Modern Drug Discovery & Development Summit held by GTCbio on October 14-16, 2009 in San Diego, CA.
- GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009.
- Dr. Joseph Bolen, CSO of Millennium to give Keynote Presentation at GTCbio's 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, MA
- GTCbio Announces its Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, Pennsylvania.
- Pete Adamson, Head of Research for Ophthiris at GlaxoSmithKline to give Keynote Presentation at GTCbio's Inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, PA.
- Alison Goss Eng of US Dept. of Energy to Present at GTCbio's Inaugural Biofuels: Science and Innovation for Sustainable Development Conference on June 29-30, 2009 in San Francisco, CA
